BACKGROUND: On the basis of the 2014 guidelines for hypertension therapy in the United States,
many eligible adults remain untreated. We projected the cost-effectiveness of treating
hypertension in U.S. adults according to the 2014 guidelines.
METHODS: We used the Cardiovascular Disease Policy Model to simulate drug-treatment and
monitoring costs, costs...
Full Text:
Guidelines
Andrew E. Moran, M.D., M.P.H., Michelle C. Odden, Ph.D.,
AnusornThanataveerat, M.P.H., Keane Y
BACKGROUND: On the basis of the 2014 guidelines for hypertension therapy in the United States,
many eligible adults remain untreated. We projected the cost-effectiveness of treating
hypertension in U.S. adults according to the 2014 guidelines.
METHODS: We used the Cardiovascular Disease Policy Model to simulate drug-treatment and
monitoring costs, costs...
BACKGROUND: On the basis of the 2014 guidelines for hypertension therapy in the United States,
many eligible adults remain untreated. We projected the cost-effectiveness of treating
hypertension in U.S. adults according to the 2014 guidelines.
METHODS: We used the Cardiovascular Disease Policy Model to simulate drug-treatment and
monitoring costs, costs...
Full Text:
MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy accord-
ing to 2014 guidelines
BACKGROUND: On the basis of the 2014 guidelines for hypertension therapy in the United States, many eligible adults remain untreated. We projected the cost-effectiveness of treating hypertension in U.S. adults according to the 2014 guidelines.
METHODS: We used the Cardiovascular Disease Policy Model to simulate drug-treatment and monitoring costs, costs...